Incidence of hepatocellular carcinoma one year after direct acting antiviral therapy for treatment of HCV infection in patients with decompensated liver cirrhosis; A multicenter s

Incidence of Acute Kidney Injury in Hospitalized Patients with Coronavirus Disease 19 Infection

Frequency of Hepatocellular Carcinoma in HCV Patients Treated with Direct-Acting Antiviral Drugs

A Study of Hepatocellular Carcinoma in Chronic Hepatitis C Patients Received Direct Acting Antiviral Drugs

HEPATOCELLULAR CARCINOMA INCIDENCE IN HEPATITIS C PATIENTS TREATED WITH DIRECT-ACTING ANTIVIRALS AND ITS RELATIONSHIP TO HEPATIC FIBROSIS STAGE

Assessment of Incidence of Hepatocellular Carcinoma among Hepatitis C Patients Who Achieved Sustained Virological Response with Direct Acting Antiviral Agents (DAAs)

Direct Acting Anti-Viral Therapy, and Potential Increase in the Incidence of Hepato-Cellular Carcinoma in Cirrhotic Patients With Hepatitis C Virus

Hepatocellular Carcinoma in Hepatitis C Virus Cirrhosis After Treatment with Direct Acting Antiviral Therapy

Outcome of Direct Acting Antiviral Drugs (DAADs) for Hepatitis C Virus (HCV) in the Setting of Chronic Kidney Disease (CKD) in Upper Egypt

The occurrence of thrombotic thrombocytopenic purpura during treatment of HCV with direct-acting antiviral agents